Programmatic approach to the prevention and control of hypertension as a key reserve for reducing mortality in the Russian Federation

Hypertension (HTN) is a powerful risk factor for cardiovascular disease and related mortality in the Russian population. The epidemiological studies ESSE-RF, ESSE-RF2, ESSE-RF3, conducted in 2012-2022, demonstrate reserves for reducing the risk of adverse events in the Russian population at all stages of the HTN control cascade. The HTN control cascade is defined based on epidemiological data and includes following patients: individuals with HTN but unaware of it; individuals with HTN who are aware of diagnosis but not taking antihypertensive medications (AHMs); patients with HTN taking AHMs but not achieving blood pressure (BP) control; patients with controlled HTN. In total, there are currently 30,4 million individuals with HTN in the Russian Federation aged 34-64 years who are unaware of their disease, are not taking AHMs, or are not achieving target BP levels. This represents the most significant potential for reducing mortality in the Russian Federation in the medium term. Barriers to achieving effective HTN control and approaches to reducing the population burden of HTN and improving the effectiveness of its management in the healthcare system are analyzed using literature data.

To improve the effectiveness of HTN control health-promoting environment in residence and workplace (including the availability of healthy foods and opportunities for exercise) should be created. It is necessary to implement preventive counseling in individual and group formats (“Health Schools”), increase the coverage of BP measurement in the population, and improve the accuracy of office BP measurement. Measures aimed at increasing medication adherence of patients, improving the quality of health care, and reducing patient costs for medications should be implemented. This article presents a programmatic approach to improving HTN control with a set of measures for each stage of HTN cascade, including measures aimed at preventing the onset of HTN, timely detection of patients and registration for outpatient monitoring, measures to improve medication adherence and the effectiveness of HTN control. In the Russian Federation, experience in implementing federal and regional HTN programs has demonstrated the rationale of this approach. Effective HTN control is possible by combining the necessary measures within a special program, since some of these measures are outside the healthcare system. A new federal HTN program would be a justified step toward increasing the active life expectancy of the Russian population.

1. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet. 2015;386:801-12. doi:10.1016/S0140-6736(14)61468-9.

2. Shalnova SA, Yarovaya EB, Metelskaya VA, et al. The relationship of arterial hypertension, elevated low-density lipoprotein cholesterol and their combination with the occurrence of new cases of cardiovascular diseases in men and women of working age. Rational Pharmacotherapy in Cardiology. 2024;20(2):183-93. (In Russ.) doi:10.20996/1819-6446-2024-3013.

3. Churilova E, Shkolnikov VM, Shalnova SA, et al. Long-term trends in blood pressure and hypertension in Russia: an analysis of data from 14 health surveys conducted in 1975-2017. BMC Public Health. 2021;21:2226. doi:10.1186/s12889-021-12320-4.

4. Richardson LC, Vaughan AS, Wright JS, et al. Examining the Hypertension Control Cascade in Adults With Uncon­trol­led Hypertension in the US. JAMA Network Open. 2024;7(9): e2431997. doi:10.1001/jamanetworkopen.2024.31997.

5. Balanova YuA, Drapkina OM, Kutsenko VA, et al. Hypertension in the Russian population during the COVID-19 pandemic: sex dif­ferences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study. Cardiovascular Therapy and Preven­tion. 2023; 22(8S):3785. (In Russ.) doi:10.15829/1728-8800-2023-3785.

6. Datta BM, Ansa BE, Husain MJ. An analytical model of population level uncontrolled hypertension management: a care cascade approach. J Human Hypertens. 2022;36(8):726-31. doi:10.1038/s41371-021-00572-x.

7. Abdalla M, Bolen SD, Brettler J, et al. Implementation Strategies to Improve Blood Pressure Control in the United States: A Scientific Statement From the American Heart Association and American Medical Association. Hypertension. 2023;80:e143-57. doi:10.1161/HYP.0000000000000232.

8. Kressin NR, Elwy AR, Glickman M, et al. Beyond medication adhe­ren­ce: the role of patients’ beliefs and life context in blood pressure control. Ethn Dis. 2019;29:567-76. doi:10.18865/ed.29.4.567

9. Petersen J, Kontsevaya A, McKee M, et al. Untreated hyper­ten­sion in Russian 35-69 year olds — a cross-­sectional study. PLoS ONE. 2020;15(5):e0233801. doi:10.1371/journal.pone.023380.

10. Muntner P, Hardy ST, Fine LJ, et al. Trends in blood pressure control among US adults with hypertension, 1999-2000 to 2017-2018. JAMA. 2020;324:1190-200. doi:10.1001/jama.2020.14545.

11. Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association. Hypertension. 2022; 79(1):e1-14. doi:10.1161/HYP.0000000000000203.

12. Milman T, Joundi RA, Alotaibi NM, et al. Clinical inertia in the phar­ma­cological management of hypertension: a systematic review and meta-analysis. Medicine (Baltimore). 2018;97:e11121. doi:10.1097/md.0000000000011121.

13. Kaiser P, Diez Roux AV, Mujahid M, et al. Neighborhood environ­ments and incident hypertension in the Multi-­Ethnic Study of Atherosclerosis. Am J Epidemiol. 2016;183:988-97. doi:10.1093/aje/kwv296.

14. Lee EY, Choi J, Lee S, et al. Objectively Measured Built Environ­ments and Cardiovascular Diseases in Middle-­Aged and Older Korean Adults. Int J Environ Res Public Health. 2021;18(4):1861. doi:10.3390/ijerph18041861.

15. Zhang D, Xu J, Hall DB, et al. The Association Between Type of Insurance Plan, Out-of-­Pocket Cost, and Adherence to Anti­hyper­tensive Medications in Medicare Supplement Insurance Enrollees. Am J Hypertens. 2024;37(8):631-9. doi:10.1093/ajh/hpae062.

16. Njie GJ, Finnie RK, Acharya SD, et al; Community Preventive Services Task Force. Reducing medication costs to prevent cardiovascular disease: a community guide systematic review. Prev Chronic Dis. 2015;12:E208. doi:10.5888/pcd12.150242.

17. Drapkina OM, Kontsevaya AV, Kalinina AM, et al. 2022 Preven­tion of chronic non-communicable diseases in the Russian Fe­de­ration. National guidelines. Cardiovascular Therapy and Pre­ven­tion. 2022;21(4):3235. (In Russ.) doi:10.15829/1728-8800-2022-3235.

18. Sarkar C, Webster C, Gallacher J. Neighbourhood walkability and incidence of hypertension: findings from the study of 429,334 UK Biobank participants. Int J Hyg Environ Health. 2018;221:458-68. doi:10.1016/j.ijheh.2018.01.009.

19. Karamnova NS, Kapustina AV, Kutsenko VA, et al. Dietary habits and all-cause mortality risk in the adult population. Results of a 6-year prospective follow-up of the ESSE-RF study cohort. Cardiovascular Therapy and Prevention. 2024;23(9):4113. (In Russ.) doi:10.15829/1728-8800-2024-4113.

20. Cogswell ME, Patel SM, Yuan K, et al. Modeled changes in US sodium intake from reducing sodium concentrations of com­mercially processed and prepared foods to meet voluntary standards established in North America: NHANES. Am J Clin Nutr. 2017;106:530-40. doi:10.3945/ajcn.116.145623.

21. Yin X, Rodgers A, Perkovic A, et al. Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis Heart. 108(20):1608-15. doi:10.1136/heartjnl-2022-321332.

22. Bernabe-­Ortiz A, Rosas G Sal Y, Ponce-­Lucero V, et al. Effect of salt sub­stitution on community-wide blood pressure and hypertension in­cidence. Nat Med. 2020;26:374-8. doi:10.1038/s41591-020-0754-2.

23. Neal B, Wu Y, Feng X, et al. Effect of Salt Substitution on Car­dio­vascular Events and Death. NEJM. 2021;385:1067-77. doi:10.1056/NEJMoa2105675.

24. Qi Z, Tang S, Hao Y, et al. Effect of salt substitute and anti­hypertensive medications among high cardiovascular risk patients: A sub-study of Salt Substitute and Stroke Study (SSaSS). J Clin Hypertens. 2024;26:1063-72. doi:10.1111/jch.14872.

25. Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. JACC. 2025;86(18):1567-678. doi:10.1016/j.jacc.2025.05.007.

26. Korhonen MJ, Pentti J, Hartikainen J, et al. Lifestyle Changes in Relation to Initiation of Antihypertensive and Lipid-­Lowering Medication: A Cohort Study. J Am Heart Assoc. 2020;9:e014168. doi:10.1161/JAHA.119.014168.

27. Chen Z, Li Q, Xu T, et al. An updated network meta-analysis of non-pharmacological interventions for primary hypertension in adults: insights from recent studies. Syst Rev. 2024;13(1):318. doi:10.1186/s13643-024-02744-5.

28. Lu Q, Zhang Y, Geng T, et al. Association of lifestyle factors and anti­hypertensive medication use with risk of All-­Cause and Cause-­Specific mortality among adults with hypertension in China. JAMA Network Open. 2022;5(2):e2146118. doi:10.1001/jamanetworkopen.2021.46118.

29. Cook R, Lamont T, Martin R, et al. Lifestyle changes may be more important than drugs for mild hypertension. BMJ. 2019;364:l571. doi:10.1136/bmj.l571.

30. Wang Y, Tuomilehto J, Jousilahti P, et al. Healthy lifestyle status, antihypertensive treatment and the risk of heart failure among Finnish men and women. J Hypertens. 2013;31(11):2158-64. doi:10.1097/HJH.0b013e328364136d.

31. Zhang Y, Tuomilehto J, Jousilahti P, et al. Lifestyle factors and an­tihypertensive treatment on the risks of ischemic and hemorrhagic stroke. Hypertension. 2012;60(4):906-12. doi:10.1161/HYPERTENSIONAHA.112.193961.

32. Hebert ET, Caughy MO, Shuval K. Primary care providers’ perceptions of physical activity counselling in a clinical setting: a systematic review. Br J Sports Med. 2012;46:625-31. doi:10.1136/bjsports-2011-090734.

33. Nguyen-­Huynh MN, Young JD, Ovbiagele B, et al. Effect of Lifestyle Coaching or Enhanced Pharmacotherapy on Blood Pressure Control Among Black Adults With Persistent Uncontrolled Hypertension: A Cluster Randomized Clinical Trial. JAMA Netw Open. 2022;5(5):e2212397. doi:10.1001/jamanetworkopen.2022.12397.

34. Drapkina OM, Drozdova LYu, Kontsevaya AV, et al. Providing Medical Care to Patients with Risk Factors for the Development of Chronic Noncommunicable Diseases in Adult Health Centers. Metodicheskie rekomendacii. Moscow: ROPNIZ, OOO SILICEA-POLIGRAF, 2025. 164 p. (In Russ.) ISBN: 978-5-6053845-8-8. doi:10.15829/ROPNIZ-d108-2025. EDN: HKMNQW.

35. Victor RG, Lynch K, Li N, et al. A Cluster-­Randomized Trial of Blood-­Pressure Reduction in Black Barbershops. N Engl J Med. 2018;378(14):1291-301. doi:10.1056/NEJMoa1717250.

36. Rotar OP, Ilyanova IN, Boyarinova MA, et al. 2023 All-­Rus­sian screening for hypertension: results. Russian Journal of Car­diology. 2024;29(5):5931. (In Russ.) doi:10.15829/1560-4071-2024-5931.

37. Holyoke P, Yogaratnam K, Kalles E. Web-­Based Smartphone Algorithm for Calculating Blood Pressure From Photoplethys­mo­graphy Remotely in a General Adult Population: Validation Study. J Med Internet Res. 2021;23(4):e19187. doi:10.2196/19187.

38. Korolev AI, Ososkov VS, Fedorovich AA, et al. Structural and functional state of the skin microcirculation in men with different phenotypes of hypertension of low and moderate cardiovascular risk. Cardiovascular Therapy and Prevention. 2024;23(10):4133. (In Russ.) doi:10.15829/1728-8800-2024-4133.

39. Jiang Q, Gong D, Li H, et al. Development and Validation of a Risk Score Screening Tool to Identify People at Risk for Hypertension in Shanghai, China. Risk Manag Health Policy. 2022;15:553-62. doi:10.2147/RMHP.S354057.

40. Egan BM, Sutherland SE, Rakotz M, et al. Improving Hypertension Control in Primary Care With the Measure Accurately, Act Ra­pidly, and Partner With Patients Protocol. Hypertension. 2018; 72(6):1320-7. doi:10.1161/HYPERTENSIONAHA.118.11558.

41. Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther. 2002;24(2):302-16. doi:10.1016/s0149-2918(02)85026-3.

42. Balanova YuA, Shalnova SA, Kutsenko VA, et al. Features of anti­hyper­tensive therapy in the Russian population: data from the ESSE-RF3 study. Rational Pharmacotherapy in Cardiology. 2024; 20(1):4-12. (In Russ.) doi:10.20996/1819-6446-2024-3010. EDN: LXJQOJ.

43. Arutyunov GP, Drapkina OM, Kobalava ZhD, et al. The concept of fixed-dose combination drugs in primary and secondary pre­ven­tion of cardiovascular disease. Position paper of the Russian So­ciety of Cardiology, the Russian Society for the Prevention of Non­com­mu­nicable Diseases, the Russian Scientific Medical Society of Inter­nal Medicine, the Russian Association of Endo­cri­no­logists, the As­so­ciation of Clinical Pharmacologists, the Eur­asian Association of In­ter­nal Medicine, the Russian Asso­cia­tion of Gerontologists and Geriatricians. Russian Journal of Cardiology. 2024;29(9):6074. (In Russ.) doi:10.15829/1560-4071-2024-6074.

44. Boytsov SA, Karpov YuA, Logunova NA, et al. Ways to increase ad­herence to antihypertensive therapy. Russian Journal of Car­dio­logy. 2022;27(9):5202. (In Russ.) doi:10.15829/1560-4071-2022-5202.

45. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for en­han­cing medication adherence. Cochrane Database Syst Rev. 2014;2014(11):CD000011. doi:10.1002/14651858.

46. Márquez Contreras E, Márquez Rivero S, Rodríguez García E, et al.; Compliance Group of Spanish Society of Hypertension (SEH-LELHA). Specific hypertension smartphone application to improve me­dication adherence in hypertension: a cluster-­randomized trial. Curr Med Res Opin. 2019;35(1):167-73. doi:10.1080/03007995.2018.1549026.

47. Lanke V, Trimm K, Habib B, Tamblyn R. Evaluating the Effec­ti­veness of Mobile Apps on Medication Adherence for Chronic Con­ditions: Systematic Review and Meta-­Analysis. J Med Internet Res. 2025;27:e60822. doi:10.2196/60822.

48. Mills KT, Obst KM, Shen W, et al. Comparative Effectiveness of Implementation Strategies for Blood Pressure Control in Hypertensive Patients: A Systematic Review and Meta-analysis. Ann Intern Med. 2018;168(2):110-20. doi:10.7326/M17-1805.

49. Clark D 3rd, Woods J, Zhang Y, et al. Home Blood Pressure Tele­monitoring With Remote Hypertension Management in a Rural and Low-­Income Population. Hypertension. 2021;78(6):1927-9. doi:10.1161/HYPERTENSIONAHA.121.18153.

50. Jiang Y, Zheng L, Zhang Y, et al. Effectiveness of the intelligent hypertension excellence centers (iHEC) therapy model in the blood pressure management of older hypertensive patients: a randomized controlled trial. Hypertens Res. 2025;48(1):15-25. doi:10.1038/s41440-024-01951-w.

51. Sakima A, Akagi Y, Akasaki Y, et al. Effectiveness of digital health interventions for telemedicine/telehealth for managing blood pressure in adults: a systematic review and meta-analysis. Hypertens Res. 2025;48(2):478-91. doi:10.1038/s41440-024-01792-7.

52. Korsunskiy DV, Boytsov SA, Kontsevaya AV, et al. Clinical efficiency of remote blood pressure monitoring in real-world practice. Cardiovascular Therapy and Prevention. 2025;24(5):4374. (In Russ.) doi:10.15829/1728-8800-2025-4374.

53. Chan WV, Pearson TA, Bennett GC, et al. ACC/AHA special report: clinical practice guideline implementation strategies: a summary of systematic reviews by the NHLBI Implementation Science Work Group: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e122-37. doi:10.1161/CIR.0000000000000481.

54. Sim JJ, Handler J, Jacobsen SJ, Kanter MH. Systemic imple­men­tation strategies to improve hypertension: the Kaiser Permanente Southern California experience. Can J Cardiol. 2014;30:544-52. doi:10.1016/j.cjca.2014.01.003.

55. Hamrahian SM, Maarouf OH, Fulop T. A critical review of medication adherence in hypertension: barriers and facilitators clinicians should consider. Patient Prefer Adher. 2022;16:2749-57. doi:10.2147/PPA.S368784.

56. Agarwal R, Gupta A, Fendrick AM. Value-based insurance design improves medication adherence without an increase in total health care spending. Health Aff (Millwood). 2018;37:1057-64. doi:10.1377/hlthaff.2017.1633.

57. Campbell NRC, Ordunez P, Giraldo G, et al. WHO HEARTS: A Global Program to Reduce Cardiovascular Disease Burden: Experience Implementing in the Americas and Opportunities in Canada. Can J Cardiol. 2021;37(5):744-55. doi:10.1016/j.cjca.2020.12.004.

58. Jaffe MG, DiPette DJ, Campbell NRC, et al. Developing population-­based hypertension control programs. Rev Panam Salud Publica. 2022;46:e153. doi:10.26633/RPSP.2022.153.

59. Valdés González Y, Campbell NRC, Pons Barrera E, et al. Imple­men­tation of a community-­based hypertension control program in Matanzas, Cuba. J Clin Hypertens (Greenwich). 2020;22(2):142-9. doi:10.1111/jch.13814.

60. Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure control associated with a large-­scale hypertension program. JAMA. 2013;310(7):699-705. doi:10.1001/jama.2013.108769.

61. Chazova IE, Oschepkova EV. Results of implementation of a hypertension control program in Russia in 2002-2012. Thera­peu­tic Archive. 2013;85(1):4-10. (In Russ.)

62. Mozheyko M, Eregin S, Danilenko N, et al. Hypertension in Russia: Changes Observed After 4 Years of a Comprehensive Health System Improvement Program in the Yaroslavl Region. J Clin Hypertens (Greenwich). 2017;19(2):198-204. doi:10.1111/jch.12885.

63. Kalinina AM. Health school for patients as a factor in increasing the effectiveness of arterial hypertension control. Trudny`j pacient. 2006:4(8):21-3. (In Russ.)

64. Azami-­Aghdash S, Joudyian N, Jafari S, et al. Assessing Com­mu­nity-­Based interventions effectiveness on hypertension pre­ven­tion and control: A systematic review and Meta-­Analysis. BMC Public Health. 2025;25(1):3253. doi:10.1186/s12889-025-24283-x.

65. Konstantinov VV, Shalnova SA, Deev AD, et al. Methodological aspects of monitoring the epidemiological situation of arterial hyper­tension among the population of the Russian Federation during the implementation of the target Federal Program "Pre­ven­tion and treatment of arterial hypertension in the Russian Fe­deration for 2002-2008". Cardiovascular Therapy and Prevention. 2007;6(2):66-70. (In Russ.)

66. Evdakov VA, Zakharchenko OO, Terentyeva DS. Detection and control of arterial hypertension is an effective tool for reducing adult mortality from diseases of the circulatory system. Social'nye aspekty zdorov'a naselenia [Social aspects of population health [serial online]. 2021;67(5):9. (In Russ.) doi:10.21045/2071-5021-2021-67-5-9.

67. Martsevich SYu, Kutishenko NP, Kalaydzhyan EP, et al. Refusal of pharmacological treatment: prevalence and clinical importance. Rational Pharmacotherapy in Cardiology. 2025;21(2):143-8. (In Russ.) doi:10.20996/1819-6446-2025-3175. EDN: MZKQEQ.

68. Kobalava Zh, Troitskaya EA, Markova MA, Khruleva YuV. Adherence of patients with arterial hypertension to a triple fixed combination of amlodipine, indapamide, and perindopril (results of the PROOF program). Arterial Hypertension. 2019;25(3):285-94. (In Russ.) doi:10.18705/1607-419X-2019-25-3-285-294.

69. Nebieridze DV, Mikhin VP, Kamyshova TV, et al. Increasing the effectiveness of arterial hypertension and dyslipidemia control in real clinical practice: results of an educational project for doctors in Kursk. Profilakticheskaya Meditsina (Preventive Medicine). 2014;6:64-70. (In Russ.)